{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:30:15Z","timestamp":1790231415631,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40265-016-0626-8","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T12:54:47Z","timestamp":1470747287000},"page":"1301-1312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease"],"prefix":"10.1007","volume":"76","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"626_CR1","unstructured":"World Health Organization. Global strategy for dengue prevention and control. 2012. http:\/\/www.who.int\/ . Accessed 1 Apr 2016."},{"key":"626_CR2","unstructured":"World Health Organization. Dengue and severe dengue: fact sheet. 2016. http:\/\/www.who.int\/ . Accessed 1 Apr 2016."},{"key":"626_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00146-8","author":"DS Shepard","year":"2016","unstructured":"Shepard DS, Undurranga EA, Halasa YA, et al. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016. doi: 10.1016\/S1473-3099(16)00146-8 .","journal-title":"Lancet Infect Dis."},{"key":"626_CR4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12985-015-0444-8","volume":"12","author":"T Nedjadi","year":"2015","unstructured":"Nedjadi T, El-Kafrawy S, Sohrab SS, et al. Tackling dengue fever: current status and challenges. Virol J. 2015;12:212.","journal-title":"Virol J."},{"key":"626_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijid.2016.01.015","volume":"44","author":"E Sarti","year":"2016","unstructured":"Sarti E, L\u2019Azou M, Mercado M, et al. A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America. Int J Infect Dis. 2016;44:44\u20139.","journal-title":"Int J Infect Dis."},{"issue":"11","key":"626_CR6","doi-asserted-by":"crossref","first-page":"e3158","DOI":"10.1371\/journal.pntd.0003158","volume":"8","author":"HG Dantes","year":"2014","unstructured":"Dantes HG, Farfan-Ale JA, Sarti E. Epidemiological trends of dengue disease in Mexico (2000\u20132011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014;8(11):e3158.","journal-title":"PLoS Negl Trop Dis."},{"issue":"11","key":"626_CR7","doi-asserted-by":"crossref","first-page":"e3027","DOI":"10.1371\/journal.pntd.0003027","volume":"8","author":"L Bravo","year":"2014","unstructured":"Bravo L, Roque VG, Brett J, et al. Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review. PLoS Negl Trop Dis. 2014;8(11):e3027.","journal-title":"PLoS Negl Trop Dis."},{"issue":"11","key":"626_CR8","doi-asserted-by":"crossref","first-page":"e3159","DOI":"10.1371\/journal.pntd.0003159","volume":"8","author":"AH Mohd-Zaki","year":"2014","unstructured":"Mohd-Zaki AH, Brett J, Ismail E, et al. Epidemiology of dengue disease in Malaysia (2000\u20132012): a systematic literature review. PLoS Negl Trop Dis. 2014;8(11):e3159.","journal-title":"PLoS Negl Trop Dis."},{"issue":"11","key":"626_CR9","doi-asserted-by":"crossref","first-page":"e3235","DOI":"10.1371\/journal.pntd.0003235","volume":"8","author":"M L\u2019Azou","year":"2014","unstructured":"L\u2019Azou M, Taurel AF, Flamand C, et al. Recent epidemiological trends of dengue in the French territories of the Americas (2000\u20132012): a systematic literature review. PLoS Negl Trop Dis. 2014;8(11):e3235.","journal-title":"PLoS Negl Trop Dis."},{"issue":"11","key":"626_CR10","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1371\/journal.pntd.0003241","volume":"8","author":"K Limkittikul","year":"2014","unstructured":"Limkittikul K, Brett J, L\u2019Azou M. Epidemiological trends of dengue disease in Thailand (2000\u20132011): a systematic literature review. PLoS Negl Trop Dis. 2014;8(11):e3241.","journal-title":"PLoS Negl Trop Dis."},{"issue":"12","key":"626_CR11","doi-asserted-by":"crossref","first-page":"e2520","DOI":"10.1371\/journal.pntd.0002520","volume":"7","author":"MG Teixeira","year":"2013","unstructured":"Teixeira MG, Siqueira JB Jr, Ferreira GL, et al. Epidemiological trends of dengue disease in Brazil (2000\u20132010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7(12):e2520.","journal-title":"PLoS Negl Trop Dis."},{"key":"626_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003499","author":"LA Villar","year":"2015","unstructured":"Villar LA, Rojas DP, Besada-Lombana S, et al. Epidemiological trends of dengue disease in Colombia (2000\u20132011): a systematic review. PLoS Negl Trop Dis. 2015. doi: 10.1371\/journal.pntd.0003499 .","journal-title":"PLoS Negl Trop Dis."},{"issue":"7","key":"626_CR13","first-page":"162","volume":"3","author":"NH Tran","year":"2012","unstructured":"Tran NH, Luong CQ, Vu TQH, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3(7):162.","journal-title":"J Vaccines Vaccin."},{"issue":"7446","key":"626_CR14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504\u20137.","journal-title":"Nature."},{"key":"626_CR15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","volume":"15","author":"G Screaton","year":"2015","unstructured":"Screaton G, Mongkolsapaya J, Yacoub Y, et al. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745\u201359.","journal-title":"Nat Rev Immunol."},{"issue":"12 Suppl","key":"626_CR16","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1038\/nrmicro2459","volume":"8","author":"RW Peeling","year":"2010","unstructured":"Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol. 2010;8(12 Suppl):S30\u20138.","journal-title":"Nat Rev Microbiol."},{"issue":"12","key":"626_CR17","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa1503877","volume":"374","author":"M L\u2019Azou","year":"2016","unstructured":"L\u2019Azou M, Moureau A, Sarti E, et al. Symptomatic dengue in children in 10 Asian and Latin American countries. N Engl J Med. 2016;374(12):1155\u201366.","journal-title":"N Engl J Med."},{"key":"626_CR18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-med-091014-090848","volume":"67","author":"B Guy","year":"2016","unstructured":"Guy B, Lang J, Saville M, et al. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387\u2013404.","journal-title":"Annu Rev Med."},{"key":"626_CR19","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","volume":"33","author":"B Guy","year":"2015","unstructured":"Guy B, Briand O, Lang J, et al. Development of the Sanofi Pastuer tetravalent dengue vaccine: one more step forward. Vaccine. 2015;33:7100\u201311.","journal-title":"Vaccine."},{"issue":"2","key":"626_CR20","first-page":"115","volume":"1","author":"N Parthiban","year":"2015","unstructured":"Parthiban N, Sivapalan N. Systematic review on immunogenicity and safety of CYD-TDV candidate vaccine. Am Med Stud Res J. 2015;1(2):115\u201325.","journal-title":"Am Med Stud Res J."},{"key":"626_CR21","unstructured":"Sanofi Pasteur. First marketing authorization of Dengvaxia\u00ae is a historic milestone paving the way to significantly impact dengue burden in endemic countries. 2015. http:\/\/www.sanofipastuer.com\/ . Accessed 1 Jan 2016."},{"key":"626_CR22","unstructured":"Sanofi Pasteur. Global introduction of the first dengue vaccine gains further momentum with this third approval in a row in an endemic country. 2015. http:\/\/www.sanofipasteur.com\/ . Accessed 1 Apr 2016."},{"key":"626_CR23","volume-title":"Dengvaxia MD, powder and solvent for suspension for injection: Philippines summary of product characteristics","author":"Sanofi Pasteur","year":"2015","unstructured":"Pasteur Sanofi. Dengvaxia MD, powder and solvent for suspension for injection: Philippines summary of product characteristics. Lyon: Sanofi Pasteur; 2015."},{"issue":"42","key":"626_CR24","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","volume":"29","author":"B Guy","year":"2011","unstructured":"Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229\u201341.","journal-title":"Vaccine."},{"issue":"11","key":"626_CR25","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.vaccine.2015.01.047","volume":"33","author":"J Dubayle","year":"2015","unstructured":"Dubayle J, Vialle S, Schneider D, et al. Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur\u2019s tetravalent CYD dengue vaccine. Vaccine. 2015;33(11):1360\u20138.","journal-title":"Vaccine."},{"issue":"10","key":"626_CR26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","volume":"32","author":"LA Villar","year":"2013","unstructured":"Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9\u201316 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32(10):1102\u20139.","journal-title":"Pediatr Infect Dis J."},{"issue":"9","key":"626_CR27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/hv.21224","volume":"8","author":"YS Leo","year":"2012","unstructured":"Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2\u201345 years: phase II randomized controlled trial in Singapore. Human Vaccin Immunother. 2012;8(9):1259\u201371.","journal-title":"Human Vaccin Immunother."},{"issue":"2","key":"626_CR28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/21645515.2015.1076598","volume":"12","author":"AP Dubey","year":"2016","unstructured":"Dubey AP, Agarkhedkar S, Chhatwal J, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Human Vaccin Immunother. 2016;12(2):512\u20138.","journal-title":"Human Vaccin Immunother."},{"issue":"49","key":"626_CR29","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2013.10.013","volume":"31","author":"A-S Hss","year":"2013","unstructured":"Hss A-S, Koh M-T, Tan KK, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2\u201311\u00a0years in Malaysia: a randomized, placebo-controlled, phase III study. Vaccine. 2013;31(49):5814\u201321.","journal-title":"Vaccine."},{"issue":"9853","key":"626_CR30","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","volume":"380","author":"A Sabchareon","year":"2012","unstructured":"Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559\u201367.","journal-title":"Lancet."},{"issue":"9951","key":"626_CR31","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","volume":"384","author":"MR Capeding","year":"2014","unstructured":"Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358\u201365.","journal-title":"Lancet."},{"issue":"2","key":"626_CR32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","volume":"372","author":"L Villar","year":"2015","unstructured":"Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113\u201323.","journal-title":"N Engl J Med."},{"issue":"6","key":"626_CR33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.13-0304","volume":"89","author":"GH Dayan","year":"2013","unstructured":"Dayan GH, Garbes P, Noriega F, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9\u201316 years in Brazil. Am J Trop Med Hyg. 2013;89(6):1058\u201365.","journal-title":"Am J Trop Med Hyg."},{"issue":"41","key":"626_CR34","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","volume":"30","author":"CF Lanata","year":"2012","unstructured":"Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine. 2012;30(41):5935\u201341.","journal-title":"Vaccine."},{"issue":"22","key":"626_CR35","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","volume":"29","author":"RZ Capeding","year":"2011","unstructured":"Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29(22):3863\u201372.","journal-title":"Vaccine."},{"issue":"3","key":"626_CR36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","volume":"201","author":"D Morrison","year":"2010","unstructured":"Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201(3):370\u20137.","journal-title":"J Infect Dis."},{"issue":"1","key":"626_CR37","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","volume":"30","author":"J Poo","year":"2011","unstructured":"Poo J, Galan F, Forrat R, et al. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30(1):e9\u201317.","journal-title":"Pediatr Infect Dis J."},{"issue":"39","key":"626_CR38","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1016\/j.vaccine.2015.08.008","volume":"33","author":"J Torresi","year":"2015","unstructured":"Torresi J, Heron LG, Qiao M, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine. 2015;33(39):5127\u201334.","journal-title":"Vaccine."},{"issue":"31","key":"626_CR39","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.vaccine.2015.05.059","volume":"33","author":"I Dorigatti","year":"2015","unstructured":"Dorigatti I, Aguas R, Donnelly CA, et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015;33(31):3746\u201351.","journal-title":"Vaccine."},{"key":"626_CR40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijid.2016.02.899","volume":"45","author":"J Menezes","year":"2016","unstructured":"Menezes J, Frago C, Laot T, et al. Integrated analysis of immunogenicity data from 11 dengue vaccine trials across 14 countries [abstract]. Int J Infect Dis. 2016;45:442.","journal-title":"Int J Infect Dis."},{"issue":"4","key":"626_CR41","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","volume":"85","author":"M Qiao","year":"2011","unstructured":"Qiao M, Shaw D, Forrat R, et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011;85(4):724\u201331.","journal-title":"Am J Trop Med Hyg."},{"key":"626_CR42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trivac.2015.03.002","volume":"4","author":"MR Capeding","year":"2015","unstructured":"Capeding MR, Laot TM, Boaz M, et al. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials Vaccin. 2015;4:19\u201323.","journal-title":"Trials Vaccin."},{"issue":"11","key":"626_CR43","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4161\/hv.25562","volume":"9","author":"A Harenberg","year":"2013","unstructured":"Harenberg A, Begue S, Mamessier A, et al. Persistence of Th1\/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Human Vaccin Immunother. 2013;9(11):2317\u201325.","journal-title":"Human Vaccin Immunother."},{"issue":"45","key":"626_CR44","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","volume":"26","author":"B Guy","year":"2008","unstructured":"Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712\u201321.","journal-title":"Vaccine."},{"issue":"Suppl 2","key":"626_CR45","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1386-6532(09)70290-2","volume":"46","author":"B Guy","year":"2009","unstructured":"Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol. 2009;46(Suppl 2):S16\u20139.","journal-title":"J Clin Virol."},{"issue":"3","key":"626_CR46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","volume":"28","author":"B Guy","year":"2010","unstructured":"Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632\u201349.","journal-title":"Vaccine."},{"issue":"13","key":"626_CR47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195\u2013206.","journal-title":"N Engl J Med."},{"issue":"1","key":"626_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.trivac.2014.07.002","volume":"3","author":"M Boaz","year":"2014","unstructured":"Boaz M, Janosczyk H, Garg S, et al. Virological confirmation of suspected dengue in a phase 2 Latin American vaccine trial: implications for vaccine efficacy evaluation. Trials Vaccinol. 2014;3(1):127\u201333.","journal-title":"Trials Vaccinol."},{"key":"626_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw297","author":"G Olivera-Botello","year":"2016","unstructured":"Olivera-Botello G, Coudeville L, Fanouillere K, et al. Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2\u201316\u00a0years in Asia and Latin America. J Infect Dis. 2016. doi: 10.1093\/infdis\/jiw297 .","journal-title":"J Infect Dis."},{"key":"626_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ptnd.0004821","author":"S Gailhardou","year":"2016","unstructured":"Gailhardou S, Skipetrova A, Dayan G, et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis. 2016. doi: 10.1371\/journal.ptnd.0004821 .","journal-title":"PLoS Negl Trop Dis."},{"key":"626_CR51","unstructured":"Sanofi Pasteur. Dengvaxia\u00ae approved in El Salvador. 2016. http:\/\/www.sanofipasteur.com\/ . Accessed 21 Apr 2016."},{"issue":"21","key":"626_CR52","first-page":"282","volume":"91","author":"WHO Strategic Advisory Group of Experts","year":"2016","unstructured":"WHO Strategic Advisory Group of Experts. Weekly epidemiological record: dengue vaccine. Wkly Epidemiol Rec. 2016;91(21):282\u20134.","journal-title":"Wkly Epidemiol Rec."},{"issue":"5","key":"626_CR53","doi-asserted-by":"crossref","first-page":"e0003655","DOI":"10.1371\/journal.pntd.0003655","volume":"9","author":"NL Achee","year":"2015","unstructured":"Achee NL, Gould F, Perkins TA, et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis. 2015;9(5):e0003655.","journal-title":"PLoS Negl Trop Dis."},{"key":"626_CR54","first-page":"115","volume":"338","author":"TW Scott","year":"2010","unstructured":"Scott TW, Morison AC. Vector dynamics and transmission of dengue virus: implications for dengue surveillance and prevention strategies. Vector dynamics and prevention strategies. Curr Top Microbiol Immunol. 2010;338:115\u201328.","journal-title":"Curr Top Microbiol Immunol."},{"key":"626_CR55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","volume":"14","author":"B Guy","year":"2016","unstructured":"Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14:45\u201354.","journal-title":"Nat Rev Microbiol."},{"key":"626_CR56","unstructured":"Sanofi Pasteur. Use of Sanofi Pasteur\u2019s dengue vaccine in endemic countries. 2016. http:\/\/www.sanofipasteur.com\/ . Accessed 14 Apr 2016."},{"key":"626_CR57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40475-013-0006-3","volume":"1","author":"L Lin","year":"2014","unstructured":"Lin L, Thomas SJ. Current dengue vaccine status. Curr Trop Med Rep. 2014;1:6\u201312.","journal-title":"Curr Trop Med Rep."},{"issue":"4","key":"626_CR58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.vaccine.2013.11.020","volume":"32","author":"I Rodriguez-Barraquer","year":"2014","unstructured":"Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Schwartz IB, et al. Potential opportunities and perils of imperfect dengue vaccines. Vaccine. 2014;32(4):514\u201320.","journal-title":"Vaccine."},{"key":"626_CR59","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1129278","author":"Y Tozan","year":"2016","unstructured":"Tozan Y. Current issues in the economics of vaccination against dengue. Expert Rev Vaccines. 2016. doi: 10.1586\/14760584.2016.1129278 .","journal-title":"Expert Rev Vaccines."},{"issue":"9951","key":"626_CR60","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(14)61142-9","volume":"384","author":"A Wilder-Smith","year":"2014","unstructured":"Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014;384(9951):1327\u20139.","journal-title":"Lancet."},{"issue":"5","key":"626_CR61","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.vaccine.2015.12.040","volume":"34","author":"PW Orellano","year":"2016","unstructured":"Orellano PW, Reynoso JI, Stahl H-C. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine. 2016;34(5):616\u201321.","journal-title":"Vaccine."},{"key":"626_CR62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijid.2016.02.897","volume":"45","author":"H Lam","year":"2016","unstructured":"Lam H, Ku GM, Wu D, et al. Cost-effectiveness analysis of dengue vaccination in the Philippines [abstract]. Int J Infect Dis. 2016;45:421.","journal-title":"Int J Infect Dis."},{"key":"626_CR63","doi-asserted-by":"crossref","unstructured":"Yeo HY, Shafie AA, Coudeville L, et al. Potential health and economic impact of introducing a dengue vaccine in Malaysia: assessment using dynamic transmission modelling [abstract no: PIN39]. In: IPSOR 18th Annual European Congress. 2015.","DOI":"10.1016\/j.jval.2015.09.1949"},{"key":"626_CR64","doi-asserted-by":"crossref","unstructured":"Yeo HY, Shafie AA, Coudeville L, et al. Exploring the cost-effective threshold price of dengue vaccination programs in Malaysia: a value-based pricing assessment [abstract no. PIN38] In: IPSOR 21st Annual International Meeting. 2016.","DOI":"10.1016\/j.jval.2016.03.1226"},{"key":"626_CR65","unstructured":"Castro R, Rueda-Gallardo JA, Avella MF, et al. Cost-effectiveness of dengue vaccine 2014 [abstract]. In: IPSOR 5th Latin America Conference. 2015."},{"key":"626_CR66","doi-asserted-by":"crossref","unstructured":"Coudeville L, Baurin N, Shepard D, et al. Potential impact and economic value of dengue vaccination in 10 endemic countries [abstract no. 41.195]. In: ICID. 2016.","DOI":"10.1016\/j.ijid.2016.02.386"},{"key":"626_CR67","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.vaccine.2016.03.017","volume":"34","author":"BD Gessner","year":"2016","unstructured":"Gessner BD, Wilder-Smith A. Estimating the public health importance of the CYD-tetravalent dengue vaccine: vaccine preventable disease incidence and numbers needed to vaccinate. Vaccine. 2016;34:2397\u2013401.","journal-title":"Vaccine."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0626-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0626-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0626-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T09:43:03Z","timestamp":1568281383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0626-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":67,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0626-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}